Trials / Completed
CompletedNCT02185053
A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc · Industry
- Sex
- All
- Age
- 50 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CPC-201 |
Timeline
- Start date
- 2014-07-31
- Primary completion
- 2016-07-31
- Completion
- 2016-07-31
- First posted
- 2014-07-09
- Last updated
- 2020-06-04
- Results posted
- 2020-06-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02185053. Inclusion in this directory is not an endorsement.